AU1189899A - Inhibition of human immunodeficiency virus (hiv-1) replication - Google Patents

Inhibition of human immunodeficiency virus (hiv-1) replication

Info

Publication number
AU1189899A
AU1189899A AU11898/99A AU1189899A AU1189899A AU 1189899 A AU1189899 A AU 1189899A AU 11898/99 A AU11898/99 A AU 11898/99A AU 1189899 A AU1189899 A AU 1189899A AU 1189899 A AU1189899 A AU 1189899A
Authority
AU
Australia
Prior art keywords
hiv
replication
inhibition
immunodeficiency virus
human immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11898/99A
Inventor
Martin E. Adelson
Kathryn T. Iacono
Robert J. Suhadolnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of AU1189899A publication Critical patent/AU1189899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU11898/99A 1997-10-16 1998-10-15 Inhibition of human immunodeficiency virus (hiv-1) replication Abandoned AU1189899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6198497P 1997-10-16 1997-10-16
US60061984 1997-10-16
PCT/US1998/021880 WO1999019496A1 (en) 1997-10-16 1998-10-15 Inhibition of human immunodeficiency virus (hiv-1) replication

Publications (1)

Publication Number Publication Date
AU1189899A true AU1189899A (en) 1999-05-03

Family

ID=22039490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11898/99A Abandoned AU1189899A (en) 1997-10-16 1998-10-15 Inhibition of human immunodeficiency virus (hiv-1) replication

Country Status (5)

Country Link
EP (1) EP1029062A1 (en)
JP (1) JP2001520017A (en)
AU (1) AU1189899A (en)
CA (1) CA2306444A1 (en)
WO (1) WO1999019496A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484251C (en) 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3901726B2 (en) * 1993-04-02 2007-04-04 リジェル・ファーマシューティカルズ・インコーポレーテッド Methods for selective inactivation of viral replication

Also Published As

Publication number Publication date
CA2306444A1 (en) 1999-04-22
JP2001520017A (en) 2001-10-30
WO1999019496A1 (en) 1999-04-22
EP1029062A1 (en) 2000-08-23

Similar Documents

Publication Publication Date Title
AU6479696A (en) Antisense inhibition of hepatitis b virus replication
AU6972798A (en) Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
AU1224100A (en) Reference clones and sequences for non-subtype b isolates of human immunodeficiency virus type 1
AU2265701A (en) Anti-hiv-1 conjugates for treatment of hiv disease
EP0853662A4 (en) Novel replication competent human immunodeficiency virus type 2 (hiv-2) proviral clone designated hiv-2kr
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
AU7700596A (en) Disposable scalpel
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU1463992A (en) Methods and pharmaceutical compositions for inhibiting protease from human immunodeficiency virus
NZ307494A (en) Lymphokine capable of inhibiting immunodeficiency viruses
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU8912698A (en) Inhibition of hiv-1 replication using d-amino acid peptides
AU4663297A (en) Inhibition of hiv replication using soluble tat peptide analogs
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
AU7465696A (en) Synthetic vaccine for protection against human immunodeficiency virus infection
AU6445798A (en) Feline immunodeficiency virus clone jsy3
AU7212694A (en) Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
AU6962894A (en) Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU1189899A (en) Inhibition of human immunodeficiency virus (hiv-1) replication
AU7666496A (en) Structure based design of inhibitors of hiv-1 reverse transcriptase
AU4767896A (en) Human immunodeficiency virus transcription inhibitors and methods of their use
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
AU2960000A (en) Detection of human immunodeficiency virus
EP1037963A4 (en) X-ray crystal comprising hiv-1 gp120

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase